NICE recommends Imbruvica, Imnovid

In updated guidance documents, the U.K.'s NICE recommended routine use of Imbruvica ibrutinib from Johnson & Johnson (NYSE:JNJ) and AbbVie Inc. (NYSE:ABBV) to treat chronic lymphocytic leukemia (CLL), and recommended Imnovid pomalidomide from Celgene Corp. (NASDAQ:CELG) to treat multiple myeloma (MM).

According to new guidance, NICE said JNJ's Janssen unit now provides Imbruvica at an undisclosed discount. As a result, the agency now recommends the drug's routine use in previously treated CLL patients or patients with a 17p deletion or TP53 mutation. Imbruvica had previously been available in the U.K. only through the Cancer Drugs Fund (CDF)...